Nicotine Replacement Therapy and Cardiovascular Disease

Ford, Catherine L.; Zlabek, Jonathan A.
May 2005
Mayo Clinic Proceedings;May2005, Vol. 80 Issue 5, p652
Academic Journal
Smoking is a well-established and important risk factor for cardiovascular disease. Cessation of smoking clearly decreases the chances of a first or subsequent cardiovascular event. Nicotine replacement therapy (NRT) is a proven adjunctive therapy to increase the probability of quitting smoking. Anecdotal reports of adverse events in patients using NRT have led some to question its safety. Is nicotine, whether in tobacco products or in NRT, the cause of the cardiovascular consequences associated with tobacco use? is using NRT to assist with smoking cessation safer than smoking? Should health care professionals avoid recommending NRT for patients with established cardiovascular disease? This article summarizes the mechanisms of harm associated with smoking and reviews the safety of NRT in both the general population and the population with cardiovascular disease, Recommendations for NRT use are offered.


Related Articles

  • Effectiveness of Nicotine Inhaler for Smoking Cessation in an OTC Setting. Leischow, Scott J.; Ranger-Moore, James; Muramoto, Myra L.; Matthews, Eva // American Journal of Health Behavior;Jul/Aug2004, Vol. 28 Issue 4, p291 

    Objective: To evaluate the effectiveness of the Nicotrol® nicotine inhaler as an aid to smoking cessation in over-the-counter (OTC) versus health-care-provider (HCP) conditions. Methods: Five hundred twenty healthy smokers were randomized to the treatment conditions and followed for a year....

  • Smoking cessation part 2: nicotine replacement therapy. Thomas, Susan // Nursing Standard;10/10/2007, Vol. 22 Issue 5, p44 

    This is the second of two articles on smoking cessation. It provides advice on helping a patient to choose an appropriate nicotine replacement therapy product.

  • Influence of smoking cessation drugs on blood pressure and heart rate in patients with cardiovascular disease or high risk score: real life setting. Pacheco Silva, André; Scholz, Jaqueline; Abe, Tania Ogawa; Pinheiro, Gabriela Gouveia; Gaya, Patricia Viviane; Costa Pereira, Alexandre; Caleb Junior Lima Santos, Paulo; Silva, André Pacheco; Pereira, Alexandre Costa; Santos, Paulo Caleb Junior Lima // BMC Cardiovascular Disorders;1/5/2016, Vol. 16, p1 

    Background: Smoking is the most important reversible cardiovascular risk factor. It is well established that quitting smoking reduces coronary events. However, on several occasions, the cardiovascular safety of smoking cessation drugs has been questioned. Our goal is to evaluate the...

  • Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Cryan, John F.; Bruijnzeel, Adrie W.; Skjei, Karen L.; Markou, Athina // Psychopharmacology;2003, Vol. 168 Issue 3, p347 

    Rationale: Bupropion is an atypical antidepres-sant and the only non-nicotine-based therapy approved for smoking cessation. Its use has raised much debate as to how a non-nicotine-based agent can aid in smoking cessation. Objectives: We assessed the effects of bupro-pion on brain reward function...

  • Smoking cessation treatment in primary care: prospective cohort study. Wilson, A.; Hippisley-Cox, J.; Coupland, C.; Coleman, T.; Britton, J.; Barrett, S. // Tobacco Control;Aug2005, Vol. 14 Issue 4, p242 

    Objective: To compare the characteristics of smokers who do and do not receive smoking cessation treatment in primary care. Design: Prospective cohort study using practices registered with the pilot QRESEARCH database. Setting: 156 550 patients aged 18 years and over from 39 general practices...

  • Nicotine gum assisted group therapy in smokers with an increased risk of coronary disease--evaluation in a primary care setting format. Basler, Heinz-Dieter; Brinkmeier, Ulrich; Buser, Kurt; Gluth, Gerhard // Health Education Research;Mar1992, Vol. 7 Issue 1, p87 

    The article presents information on a study related to nicotine gum therapy for treatment of coronary diseases among smokers. The study describes a comprehensive behavioral smoking cessation programs by using nicotine chewing gum consonant with the needs of primary care. The study evaluates the...

  • Telephone support as an adjunct to transdermal nicotine in smoking cessation. Lando, Harry A.; Rolnick, Sharon; Klevan, David; Roski, Joachim; Cherney, Linda; Lauger, Gary // American Journal of Public Health;Oct97, Vol. 87 Issue 10, p1670 

    Objectives. Transdermal nicotine patches have shown considerable promise in improving smoking cessation outcomes. The present study assessed telephone support as an adjunct to a managed care-based, single-session group orientation smoking cessation program with nicotine patch therapy. Methods....

  • New drug helps more quit than bupropion.  // GP: General Practitioner;11/25/2005, p14 

    The article reports on a new drug, which helps in quitting smoking. A new treatment to help smokers quit has been found to be more effective than the widely prescribed bupropion and more than twice as effective as trying to give up without drugs. The drug works as a partial nicotine agonist. It...

  • Nicotine Absorption From Seven Current Nicotine Replacement Products and a New Wide-Bore Nicotine Delivery Device. McEwen, Andy; West, Robert; Gaiger, Maria // Journal of Smoking Cessation;Dec2008, Vol. 3 Issue 2, p117 

    This preliminary laboratory study investigated nicotine absorption rates of seven current nicotine replacement therapy (NRT) products and a new wide-bore nicotine delivery device (the ‘Nicotine Cannon’). The nicotine products (Cannon, inhalator, nasal spray, microtab, 2 mg and 4 mg...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics